Gene: AGMO
Official Full Name: alkylglycerol monooxygenaseprovided by HGNC
Gene Summary: The protein encoded by this gene is a tetrahydrobiopterin- and iron-dependent enzyme that cleaves the ether bond of alkylglycerols. Sequence comparisons distinguish this protein as forming a third, distinct class of tetrahydrobiopterin-dependent enzymes. Variations in this gene have been associated with decreased glucose-stimulated insulin response, type 2 diabetes, and susceptibility to intracranial aneurysms. [provided by RefSeq, Aug 2012]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO19933 | AGMO Knockout cell line (A549) | Human | AGMO | 1:3~1:4 | Negative | Online Inquiry |
AGMO Gene Knockout Cell Lines are advanced biological products meticulously developed to facilitate targeted gene editing in a range of research applications. These cell lines are engineered using the CRISPR-Cas9 technology, which allows for the precise disruption of specific genes, thereby offering researchers a powerful tool to elucidate gene function, protein interactions, and the underlying mechanisms of various biological processes.
The key mechanism of AGMO Gene Knockout Cell Lines lies in their ability to introduce double-strand breaks at designated loci in the genome. This induces the cell's repair machinery to either insert or delete segments of DNA, resulting in the knockout of the targeted gene. By studying these knockout models, researchers can gain insights into gene function, phenotype expression, and pathways involved in health and disease.
The scientific importance of AGMO Gene Knockout Cell Lines is substantial, as they play a pivotal role in advancing both basic and translational research. Their applications range from pharmacogenomics to oncology and gene therapy, offering researchers the possibility to explore disease mechanisms and develop novel therapeutic strategies. In clinical settings, these cell lines are instrumental for drug development, allowing for the screening of therapeutic compounds against well-defined genetic backgrounds.
What sets AGMO Gene Knockout Cell Lines apart from alternative products is their unparalleled specificity and efficiency in gene editing, alongside the comprehensive validation process ensuring their reliability in experimental settings. Furthermore, AGMO's commitment to quality control and reproducibility guarantees that researchers can confidently replicate results across studies.
For researchers and clinicians, the value of AGMO Gene Knockout Cell Lines resides not only in their ability to accelerate discoveries but also in their potential to transform scientific insights into actionable healthcare solutions. Our company prides itself on expertise in genetic engineering and a robust portfolio of biological products that support cutting-edge research, making us a trusted partner in the scientific community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.